Skip to main content

Clifford Chance

Clifford Chance
News and awards

News and awards

Clifford Chance advised Informa on the completion of its divestment of Pharma Intelligence for £1.9 billion to Warburg Pincus

1 June 2022

Clifford Chance advised Informa on the completion of its divestment of Pharma Intelligence for £1.9 billion to Warburg Pincus

International law firm Clifford Chance has advised long-standing FTSE 100 client Informa, the international B2B Markets, Knowledge Services and Business Intelligence Group, on the completion of its divestment of Pharma Intelligence, its largest business within the Informa Intelligence division to Warburg Pincus for £1.9bn.

Following signing on 17 February 2022, on which Clifford Chance also advised Informa, the sale of the Pharma Intelligence business successfully completed on 1 June 2022.

This transaction plays a key part in Informa's 2021-2024 Growth Acceleration Plan II, and provide funds to accelerate investment and expansion in two priority areas: Academic Markets & Knowledge Services (Taylor & Francis) and B2B Markets & Digital Services (Informa Markets, Informa Connect, Informa Tech). The proceeds of sale are also intended to be deployed as part of Informa's stated intention of returning £1bn of embedded value to shareholders through the combination of a share buyback programme and a special dividend.

This transaction was led by Corporate Partner Steven Fox who commented:

"We are delighted to have assisted Informa to implement this significant strategic transaction which will provide funds to accelerate investment and expansion in two priority areas for Informa. The exceptional commitment of Informa's Legal and Corporate Development teams, and collaboration of Clifford Chance colleagues across our global platform and offices in the UK, New York, Sydney and Luxembourg successfully delivered the divestment for Informa."